Particle.news
Download on the App Store
5 ARTICLES
·
last wk.

Gland Pharma Q4 FY25 Results Miss Estimates as US Revenue Declines

The company reports a 3% profit drop and 7.3% revenue fall, while declaring an Rs 18 dividend to shareholders.

Image
Image
'Battling on multiple fronts': Gland Pharma shares up 5% despite subdued Q4; here's target price

Overview

  • Gland Pharma's Q4 FY25 net profit declined 3% year-on-year to Rs 186 crore, missing analyst expectations of Rs 233 crore.
  • Quarterly revenue fell 7.3% to Rs 1,425 crore, driven by a 10% drop in US market sales, its largest revenue contributor.
  • Despite lower expenses, EBITDA decreased 0.7% to Rs 347.4 crore, falling short of the Rs 376 crore estimate.
  • The board proposed a final dividend of Rs 18 per share for FY25, with a record date set for August 14, 2025.
  • Market reactions remain volatile as investors assess the earnings miss and the company's focus on diversifying into complex injectables and biologics.